Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Endometrial Neoplasms 12Polycystic Ovary Syndrome 4Endometrial Hyperplasia 4Infertility 3Neoplasms 2Anovulation 2Vitamin D Deficiency 1Turcot syndrome 1Overweight 1Obesity 1Menorrhagia 1Leiomyoma 1FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma 1Endometrial Adenocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Endometrioid 1Breast Neoplasms 1Advanced, Persistent, or Recurrent Endometrial Cancer 1Adenocarcinoma 1

Interventions

pembrolizumab 10Nivolumab 9Ipilimumab 4avelumab 3Neoadjuvant Therapy 3toripalimab 2sintilimab 2durvalumab 2atezolizumab 2Specimen Handling 2Immune Checkpoint Inhibitors 2Celecoxib 2tislelizumab 1spartalizumab 1relatlimab 1regorafenib 1fludarabine phosphate 1fludarabine 1dostarlimab 1denileukin diftitox 1danvatirsen 1camrelizumab 1XELOX 1Taxes 1Surgical Procedures, Operative 1Radiation Dose Hypofractionation 1Paclitaxel 1Oxaliplatin 1Megestrol Acetate 1Medroxyprogesterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Turcot syndrome × Medroxyprogesterone Acetate × Clear all
NCT06549855 2024-08-12

PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer

Peking University People's Hospital

Phase NA Not yet recruiting
10 enrolled
Gynecologic

Turcot syndrome, Endometrial Neoplasms, Carcinoma, Endometrioid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡